Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Strekin AG (www.strekin.com), a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3 clinical trial of the investigational drug STR001 in patients following a Sudden Sensorineural Hearing Loss (SSNHL) event. RESTORE is evaluating the ability of STR001 given by intratympanic injection with and without 3-month oral follow-up with STR001 tablets to restore hearing in SSNHL. RESTORE has completed enrollment of the target of 165 patients at approximately 25 clinical centers across 5 European countries. STR001 has been very well tolerated and topline results from RESTORE are anticipated to be released in early 2020.

"We are pleased to have completed patient enrollment in the Phase 3 RESTORE clinical trial which is designed to evaluate the ability of STR001 activity to reverse hearing loss following a SSNHL event," remarked Alexander Bausch, Chief Executive Officer of Strekin. "The RESTORE trial tests the ability of STR001 to address a clear unmet medical need in patients who have suffered severe hearing loss that may lead to a debilitating life-long handicap. If successful, the data provided by RESTORE, along with the orphan drug status of STR001 for SSNHL in the EU, may enable STR001 to become the first approved treatment for SSNHL patients."

About STR001

STR001 is a small molecule agonist of the Peroxisome Proliferator Activated Receptor gamma (PPAR-g), which plays multiple beneficial roles in inflammation, oxidative stress, and cellular metabolism. Preclinical data published by Strekin and its collaborators demonstrated that STR001 effectively protects hearing in animal models by blocking oxidative stress and reducing activation of inflammatory signaling in the cochlea. Animal efficacy data were published in October 2018 in the journal Frontiers in Pharmacology and are available on an open access basis at the following: (https://doi.org/10.3389/fphar.2018.01103).

About Sudden Sensorineural Hearing Loss

Sudden Sensorineural Hearing Loss (SSNHL) is an acute loss of hearing caused by damage to the sound-sensing hair cells of the inner ear. SSHNL may be caused by surgery, acoustic trauma, or sudden deafness, a phenomenon in which hearing loss occurs without obvious cause. Further symptoms may include ringing in the ears (tinnitus) and dizziness (vertigo). Sudden hearing loss is a medical emergency. Individuals who perceive a sudden change in their hearing are recommended to contact their health care provider without delay. Hearing loss makes daily activities most people take for granted, like having a conversation, enjoying music, and communicating effectively in the work environment, difficult or impossible. There are currently no approved drugs available for the treatment of SSNHL.

About Strekin

Strekin AG (www.strekin.com) is a Swiss-based biopharmaceutical company advancing therapeutics for improved patient benefit in diseases with high unmet need. Strekin is led by a team of experts with extensive experience in successful discovery, development, and commercialization of new drugs. Strekin is privately funded by a broad base of investors.

Tags : #strekin #patientrecruitment #technology #healthcare #STR001

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Is Your Cooking Oil Poisoning You? The Truth About Seed OilsMarch 11, 2025
Think Before You Bite: How Fatty Foods Can Trigger Brain Damage in Just 3 DaysMarch 11, 2025
Ditch the Pills: The Secret to Beating Insomnia is in Your WorkoutMarch 11, 2025
The University of Tasmania invites applications for Master of Public HealthMarch 11, 2025
CBM India Celebrates International Women's Day with Free Eye Screening in HyderabadMarch 11, 2025
Is patriarchy petrifying governments to deliver on gender equality?March 11, 2025
Change happens when gender inequality survivors join hands to stop TB March 10, 2025
Arogya World Hosts #RunInRed With 1500+ Bengalureans To Raise Awareness on Women’s Heart HealthMarch 10, 2025
Sharda Group Launches Sharda Care - Healthcity, a State-of-the-Art Facility with Smart Infrastructure in Greater NoidaMarch 10, 2025
Can Just Three Days of Junk Food Harm Your Brain? Science Says YesMarch 08, 2025
Your Night Shifts Might Be Damaging Your DNA: Here’s How to Fight BackMarch 08, 2025
India’s Women: Empowered on Paper, Struggling in RealityMarch 08, 2025
NephroPlus to Launch Nationwide Free Health Screening Campaign to Commemorate World Kidney Day 2025 March 07, 2025
Skinny But Sick? Is our Body Mass Index Misleading UsMarch 07, 2025
Scientists Stumble Upon a Cancer-Fighting Secret Hidden in Your Medicine CabinetMarch 07, 2025
The Bitter Truth About Butter: Is our Favourite Spread Cutting our Life Short?March 07, 2025
March 07, 2025
March 06, 2025
University of Leeds scientists offer hope for people facing chronic painMarch 06, 2025
Impact of excessive use of gym supplements on gym enthusiastsMarch 06, 2025